Michel Pelat
Overview
Explore the profile of Michel Pelat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pelat M, Barbe F, Daveu C, Ly-Nguyen L, Lartigue T, Marque S, et al.
J Pharmacol Exp Ther
. 2021 Feb;
377(2):293-304.
PMID: 33602875
In failing hearts, Na/Ca exchanger (NCX) overactivity contributes to Ca depletion, leading to contractile dysfunction. Inhibition of NCX is expected to normalize Ca mishandling, to limit afterdepolarization-related arrhythmias, and to...
2.
Ozoux M, Briand V, Pelat M, Barbe F, Schaeffer P, Beauverger P, et al.
J Pharmacol Exp Ther
. 2020 Apr;
374(1):24-37.
PMID: 32332113
Chronic kidney disease (CKD) remains a common disorder, leading to growing health and economic burden without curative treatment. In diabetic patients, CKD may result from a combination of metabolic and...
3.
Desjardins F, Lobysheva I, Pelat M, Gallez B, Feron O, Dessy C, et al.
Cardiovasc Res
. 2008 Mar;
79(3):527-36.
PMID: 18349137
Aims: In endothelial cells, caveolin-1 (cav-1) is known to negatively modulate the activation of endothelial nitric oxide synthase, a key regulator of blood pressure (BP). However, the impact of genetic...
4.
Desjardins F, Sekkali B, Verreth W, Pelat M, De Keyzer D, Mertens A, et al.
Eur Heart J
. 2007 Dec;
29(1):128-37.
PMID: 18063594
Aims: Statins improve atherosclerotic diseases through cholesterol-reducing effects. Whether the latter exclusively mediate similar benefits, e.g. on hypertension, in the metabolic syndrome is unclear. We examined the effects of rosuvastatin...
5.
Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N, et al.
Circ Res
. 2005 Dec;
98(2):280-8.
PMID: 16373598
Ischemic preconditioning confers powerful protection against myocardial infarction through pre-emptive activation of survival signaling pathways, but it remains difficult to apply to patients with ischemic heart disease, and its effects...
6.
Hedhli N, Pelat M, Depre C
Cardiovasc Res
. 2005 Aug;
68(2):186-96.
PMID: 16061215
Protein turnover represents the balance between protein synthesis and degradation. It can be controlled quantitatively, for instance by an activation of protein synthesis during cardiac hypertrophy or by activating protein...
7.
Massion P, Pelat M, Belge C, Balligand J
Comp Biochem Physiol A Mol Integr Physiol
. 2005 Jun;
142(2):144-50.
PMID: 15985381
The mammalian heart expresses all three isoforms of nitric oxide synthases (NOS) in diverse cell types of the myocardium. Despite their apparent promiscuity, the NOS isoforms support specific signaling because...
8.
Pelat M, Balligand J
Semin Vasc Med
. 2005 Apr;
4(4):367-75.
PMID: 15861317
Hypertension and dyslipidemia are frequently associated as risk factors for cardiovascular diseases. Statins are among the most potent drugs to correct hypercholesterolemia, and their use across a wide range of...
9.
Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki J, et al.
Circulation
. 2004 Nov;
110(20):3259-69.
PMID: 15533870
Background: Weight loss in obese insulin-resistant but not in insulin-sensitive persons reduces coronary heart disease risk. To what extent changes in gene expression are related to atherosclerosis and cardiovascular function...
10.
Massion P, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C, et al.
Circulation
. 2004 Oct;
110(17):2666-72.
PMID: 15492314
Background: In the heart, nitric oxide synthases (NOS) modulate cardiac contraction in an isoform-specific manner, which is critically dependent on their cellular and subcellular localization. Defective NO production by NOS3...